These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7904763)

  • 1. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
    Stevens A; Stevens I; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.
    McManus DQ; Arvanitis LA; Kowalcyk BB
    J Clin Psychiatry; 1999 May; 60(5):292-8. PubMed ID: 10362435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    Meltzer HY; Jayathilake K
    J Clin Psychiatry; 1999; 60 Suppl 10():47-51. PubMed ID: 10340687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acutely ill schizophrenic patients treated with loxapine. A clinical study in a community mental health center.
    Rasul M
    Clin Ther; 1980; 3(4):242-9. PubMed ID: 7273062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic prescription for Chinese schizophrenics in Hong Kong.
    Chiu H; Lee S; Leung CM; Wing YK
    Aust N Z J Psychiatry; 1992 Jun; 26(2):262-4. PubMed ID: 1353673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
    Bobon D; Troisfontaines B; Kempeneers JL; Xhenseval B; Bourdouxhe S; Mirel J; Gilson H; Toussaint C; von Frenckell R; Pedersen V
    Acta Psychiatr Belg; 1986; 86(2):152-76. PubMed ID: 2873713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
    Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population.
    Dunlop SR; Shea PA; Hendrie HC
    Biol Psychiatry; 1982 Aug; 17(8):929-36. PubMed ID: 6126231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melperone in the treatment of neuroleptic-resistant schizophrenia.
    Meltzer HY; Sumiyoshi T; Jayathilake K
    Psychiatry Res; 2001 Dec; 105(3):201-9. PubMed ID: 11814539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose versus low-dose strategies in the treatment of schizophrenia.
    Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M
    Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848
    [No Abstract]   [Full Text] [Related]  

  • 20. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.